2 results
Approved WMOCompleted
The goal of this study is to prove whether kidney transplant recipients can reduce their risk of cardiovascular disease bij converting to Nulojix.
Approved WMORecruiting
Objective: To compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, withrespect to progression-free survival (PFS) per RECIST 1.1 as assessed by the investigator.